Evidence map›Paper›PMID 31177328›Full record

ArticleCancer immunology, immunotherapy : CII2019

An HER2 DNA vaccine with evolution-selected amino acid substitutions reveals a fundamental principle for cancer vaccine formulation in HER2 transgenic mice.

Richard F Jones, Joyce D Reyes, Heather M Gibson, Jennifer B Jacob, Ulka Vaishampayan, Stuart Ratner, Kang Chen, Wei-Zen Wei

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Richard F JonesDepartment of Oncology, Karmanos Cancer Institute, Wayne State University, 4100 John R. Street, Detroit, MI, 48201, USA.
Joyce D ReyesDepartment of Oncology, Karmanos Cancer Institute, Wayne State University, 4100 John R. Street, Detroit, MI, 48201, USA.
Heather M GibsonDepartment of Oncology, Karmanos Cancer Institute, Wayne State University, 4100 John R. Street, Detroit, MI, 48201, USA.
Jennifer B JacobDepartment of Oncology, Karmanos Cancer Institute, Wayne State University, 4100 John R. Street, Detroit, MI, 48201, USA.
Ulka VaishampayanDepartment of Oncology, Karmanos Cancer Institute, Wayne State University, 4100 John R. Street, Detroit, MI, 48201, USA.
Stuart RatnerDepartment of Oncology, Karmanos Cancer Institute, Wayne State University, 4100 John R. Street, Detroit, MI, 48201, USA.
Kang ChenDepartment of Oncology, Karmanos Cancer Institute, Wayne State University, 4100 John R. Street, Detroit, MI, 48201, USA.
Wei-Zen WeiDepartment of Oncology, Karmanos Cancer Institute, Wayne State University, 4100 John R. Street, Detroit, MI, 48201, USA. weiw@karmanos.org.
The Barbara Ann Karmanos Cancer Institute · USWayne State University · US

Funding

DEVELOPMENT OF ERBB2 BASED BREAST CANCER VACCINESR01CA076340 · NCI · WAYNE STATE UNIVERSITY · PI WEI, WEI-ZEN · 1998 to 2020
$5.2M
Directing Cancer Immunotherapy with Real-Time ImmunoPETR21CA216648 · NCI · WAYNE STATE UNIVERSITY · PI VIOLA, NERISSA THERESE, WEI, WEI-ZEN · 2017 to 2018
$368k
NCI NIH HHS CA076340NCI NIH HHS CA216648NCI NIH HHS R01 CA076340NCI NIH HHS R21 CA216648
6 · The paper itself

Abstract

Enhancement of endogenous immunity to tumor-associated self-antigens and neoantigens is the goal of preventive vaccination. Toward this goal, we compared the efficacy of the following HER2 DNA vaccine constructs: vaccines encoding wild-type HER2, hybrid HER2 vaccines consisting of human HER2 and rat Neu, HER2 vaccines with single residue substitutions and a novel human HER2 DNA vaccine, ph(es)E2TM. ph(es)E2TM was designed to contain five evolution-selected substitutions: M198V, Q398R, F425L, H473R and A622T that occur frequently in 12 primate HER2 sequences. These ph(es)E2TM substitutions score 0 to 1 in blocks substitutions matrix (BLOSUM), indicating minimal biochemical alterations. h(es)E2TM recombinant protein is recognized by a panel of anti-HER2 mAbs, demonstrating the preservation of HER2 protein structure. Compared to native human HER2, electrovaccination of HER2 transgenic mice with ph(es)E2TM induced a threefold increase in HER2-binding antibody (Ab) and elevated levels of IFNγ-producing T cells. ph(es)E2TM, but not pE2TM immune serum, recognized HER2 peptide p95

Indexed as

Amino Acid SubstitutionAnimalsAntigens, NeoplasmCancer VaccinesCell Line, TumorDendritic CellsErb-b2 Receptor Tyrosine KinasesEvolution, MolecularFemaleImmunogenicity, VaccineImmunotherapyMammary Neoplasms, ExperimentalMiceMice, Inbred BALB CMice, TransgenicRecombinant ProteinsAntigens, NeoplasmCancer VaccinesERBB2 protein, humanErbb2 protein, mouseErb-b2 Receptor Tyrosine KinasesRecombinant ProteinsVaccines, DNACancer vaccineEvolution selectedHER2HumanPrimate

Identifiers

PMID31177328
PMCPMC6586491
OpenAlexW2952630790

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.